Legal & General Group
FOLD

Legal & General Group’s Amicus Therapeutics FOLD Stock Holding History

Legal & General Group’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.48M Sell
240,554
-42,453
-15% -$609K ﹤0.01% 1679
2025
Q4 		$4.03M Buy
283,007
+18,899
+7% +$186K ﹤0.01% 1678
2025
Q3 		$2.08M Sell
264,108
-800
-0.3% -$5.69K ﹤0.01% 1963
2025
Q2 		$1.52M Buy
264,908
+8,375
+3% +$54K ﹤0.01% 2081
2025
Q1 		$2.09M Sell
256,533
-531
-0.2% -$4.91K ﹤0.01% 1903
2024
Q4 		$2.42M Buy
257,064
+7,275
+3% +$75.6K ﹤0.01% 1896
2024
Q3 		$2.67M Buy
249,789
+22,133
+10% +$241K ﹤0.01% 1853
2024
Q2 		$2.26M Buy
227,656
+4,201
+2% +$43.1K ﹤0.01% 1890
2024
Q1 		$2.63M Buy
223,455
+6,495
+3% +$83.1K ﹤0.01% 1807
2023
Q4 		$3.08M Buy
216,960
+2,719
+1% +$30.9K ﹤0.01% 1742
2023
Q3 		$2.61M Buy
214,241
+4,169
+2% +$53.8K ﹤0.01% 1777
2023
Q2 		$2.64M Sell
210,072
-33,060
-14% -$392K ﹤0.01% 1789
2023
Q1 		$2.7M Sell
243,132
-108,499
-31% -$1.34M ﹤0.01% 1742
2022
Q4 		$4.29M Buy
351,631
+31,225
+10% +$352K ﹤0.01% 1489
2022
Q3 		$3.35M Buy
320,406
+99,960
+45% +$1.11M ﹤0.01% 1588
2022
Q2 		$2.37M Sell
220,446
-2,811
-1% -$23.1K ﹤0.01% 1799
2022
Q1 		$2.11M Buy
223,257
+15,686
+8% +$147K ﹤0.01% 1961
2021
Q4 		$2.4M Buy
207,571
+160
+0.1% +$1.78K ﹤0.01% 1944
2021
Q3 		$1.98M Buy
207,411
+41,452
+25% +$424K ﹤0.01% 2027
2021
Q2 		$1.6M Buy
165,959
+2,173
+1% +$21.2K ﹤0.01% 2069
2021
Q1 		$1.62M Buy
163,786
+81
+0% +$1.25K ﹤0.01% 2064
2020
Q4 		$3.78M Buy
163,705
+9,791
+6% +$200K ﹤0.01% 1609
2020
Q3 		$2.17M Sell
153,914
-11,166
-7% -$163K ﹤0.01% 1732
2020
Q2 		$2.49M Buy
165,080
+10,684
+7% +$130K ﹤0.01% 1642
2020
Q1 		$1.43M Sell
154,396
-7,398
-5% -$70.3K ﹤0.01% 1730
2019
Q4 		$1.58M Buy
161,794
+30,886
+24% +$283K ﹤0.01% 1908
2019
Q3 		$1.05M Buy
130,908
+16,166
+14% +$175K ﹤0.01% 1974
2019
Q2 		$1.43M Buy
114,742
+30,909
+37% +$392K ﹤0.01% 1837
2019
Q1 		$1.14M Buy
83,833
+998
+1% +$12.2K ﹤0.01% 1925
2018
Q4 		$793K Buy
82,835
+16,234
+24% +$178K ﹤0.01% 1978
2018
Q3 		$805K Hold
66,601
– – ﹤0.01% 2010
2018
Q2 		$1.04M Sell
66,601
-4,829
-7% -$73K ﹤0.01% 1913
2018
Q1 		$1.07M Buy
71,430
+1,479
+2% +$22.5K ﹤0.01% 1862
2017
Q4 		$1.01M Sell
69,951
-1,334
-2% -$18.3K ﹤0.01% 1879
2017
Q3 		$1.07M Buy
71,285
+15,874
+29% +$210K ﹤0.01% 1843
2017
Q2 		$558K Buy
55,411
+852
+2% +$6.86K ﹤0.01% 2029
2017
Q1 		$390K Sell
54,559
-548
-1% -$3.46K ﹤0.01% 2090
2016
Q4 		$273K Buy
55,107
+15,396
+39% +$107K ﹤0.01% 2136
2016
Q3 		$288K Buy
39,711
+9,941
+33% +$67.1K ﹤0.01% 1933
2016
Q2 		$162K Hold
29,770
– – ﹤0.01% 1853
2016
Q1 		$244K Buy
29,770
+3,743
+14% +$26.5K ﹤0.01% 1662
2015
Q4 		$249K Buy
26,027
+5,406
+26% +$48.7K ﹤0.01% 1656
2015
Q3 		$283K Buy
20,621
+5,264
+34% +$82.6K ﹤0.01% 1529
2015
Q2 		$213K Buy
+15,357
New +$185K ﹤0.01% 1715

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Legal & General Group's FOLD Position: Q1 2026 in Review

Legal & General Group reduced its Amicus Therapeutics (FOLD) stake by 15% in Q1 2026, selling an estimated $609K and leaving 240,554 shares worth $3.48M. The position accounts for ﹤0.01% of the portfolio, ranked #1679.

Legal & General Group first reported a position in FOLD in Q2 2015 and has held it in 44 quarters since. The position peaked at $4.29M in Q4 2022. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Legal & General Group held 240,554 shares of Amicus Therapeutics worth $3.48M as of Q1 2026.
  • Legal & General Group sold 42,453 Amicus Therapeutics shares in Q1 2026, an estimated $609K.
  • Amicus Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #1679 holding.
  • Legal & General Group first reported a position in Amicus Therapeutics in Q2 2015 and has held it in 44 quarters since.
  • Legal & General Group's Amicus Therapeutics position peaked at $4.29M in Q4 2022.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.